Latest epileptic seizure Stories

-- 4 Paws for Ability Service Dogs to Greet Visitors at Eisai Event Booth -- WOODCLIFF LAKE, N.J., April 18, 2013 /PRNewswire/ -- Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7(th) Annual National Walk for Epilepsy, a family-oriented, non-competitive event to raise awareness and funds to continue fighting to stop seizures, find a cure and overcome the challenges created by epilepsy. The Walk, which unites thousands of families living with...

DUBLIN, April 17, 2013 /PRNewswire/ -- Research and Markets announces the addition of "EpiCast Report: Epilepsy - Epidemiology Forecast to 2022" to its catalogue.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Epilepsy affects 50 million people worldwide each year and is one of the most common neurological conditions in the world (WHO, 2005). Epilepsy is defined as a collection of brain dysfunction disorders characterized by recurrent and unpredictable seizures. The...

The seizures that affect people with temporal-lobe epilepsy usually start in a region of the brain called the hippocampus. But they are often able to involve other areas outside the temporal lobe, propagating via anatomically and functionally connected networks in the brain. New research findings that link decreased brain cell concentration to altered functional connectivity in temporal-lobe epilepsy are reported in an article in Brain Connectivity, a bimonthly peer-reviewed publication from...

EEG could be more widely used to identify treatable causes of common disorders in hospital patients, say researchers in Mayo Clinic Proceedings A retrospective study of patients who had in-hospital electroencephalography (EEG) has established that EEG is a valuable tool that could be deployed more widely to identify treatable causes of impaired consciousness in the hospital setting. The study is published in the April issue of the Mayo Clinic Proceedings. Altered mental status (AMS) and...

E-Action(TM) designed for the 300,000 living with the neurological disorder(1) OAKVILLE, ON, March 26, 2013 /CNW/ - Canadians with epilepsy, as well as their family, friends and caregivers, now have an exciting new information source and support network. E-Action(TM) - Taking Action Against Epilepsy strives to provide a caring and informative environment for those touched by the disorder. E-Action(TM) includes a broad range of interactive education and information resources,...

- Researchers will study factors influencing optimal epilepsy outcomes ATLANTA, March 25, 2013 /PRNewswire/ -- A research collaboration to analyze the clinical factors that impact epilepsy care and outcomes was announced today by the Department of Neurology at Emory University School of Medicine and UCB, a leading biopharmaceutical company. This work is part of an innovative research collaboration that seeks to identify factors and approaches that achieve optimal response in epilepsy...

UCLA Case Study Results To Be Presented At Major International Status Epilepticus Conference In Salzburg, Austria LOS ANGELES, March 25, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that it will exhibit its CE Mark approved, non-invasive Monarch(TM) eTNS(TM) System for the adjunctive treatment of epilepsy and depression, at the 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures to be held in Salzburg, Austria...

USL261 Demonstrated Improved Bioavailability of Midazolam, Similar Pharmacodynamic Effects, and Comparable Tolerability as Compared with Injectable Midazolam Administered Intranasally in Healthy Volunteers MAPLE GROVE, Minn., March 19, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., (Upsher-Smith) today announced that Phase I data for USL261 (intranasal midazolam) in healthy volunteers were presented at the Annual American Academy of Neurology (AAN) Meeting in San Diego, CA....

MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65(th) Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013. Upsher-Smith's CNS pipeline consists of...

Lawrence LeBlond for redOrbit.com - Your Universe Online A medical device company recently received funding from a branch of the National Institutes of Health (NIH) to conduct a new two-Phase clinical trial for an internally-implanted electronic device that may help treat epilepsy. NeuroSigma Inc., the company behind the device, is basing the new trial on evidence of another similar device, an electronic patch that has been shown to reduce symptoms of depression by up to 50 percent....